The large body of evidence, showing that PACAP is protective in animal models of several diseases, places PACAP on the list of emerging protective therapeutic agents in neurodegenerative disorders (Cheng et al. 2020; Soles-Tarres et al. 2020) and stroke (Cherait et al. 2021; Fang et al. 2020; Sadanandan et al. 2021; Zheng et al. 2021). Here, ADCYAP1 is linked to stroke disorder.